HeartWare Points To Less Acute Patients As One Key To HVAD Success
This article was originally published in The Gray Sheet
Executive SummaryAs HeartWare awaits an approval decision for its first left ventricular assist device, the company says it is continuing to advance its pipeline and push forward with a longer-term strategy to maximize the treatable population for the product.
You may also be interested in...
Investigators for the REVIVE-IT pilot study received a second deficiency letter from FDA May 11; researchers say they continue to work with the agency to move forward on the 100-patient, randomized trial.